BioSpace News Archive

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers is pleased to announce that it has completed the final engineering of IzoView.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD),

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has received a Notice of Allowance for its US Patent Application 16/224,590 titled “Magnetic Resonance Spectroscopy System and Method for Diagnosing Pain or Infection Associated with Propionic Acid”.

LAVAL, QC / ACCESSWIRE / November 4, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (“Bausch Health”) and its gastroenterology business, Salix Pharmaceuticals (“Salix”), today announced one de novo abstract that is being presented at The Liver Meeting® 2022 , organized by the American Association for the Study of Liver Diseases (AASLD), which is taking place November 4-8 in Washington, D.C. The abstract being presented at AASLD’s The Liver Meeting 2022 is:

Millstone Medical Outsourcing, the industry’s leading partner of choice for medical manufacturers’ post-manufacturing and aftermarket services, announces its completed acquisition of Ethide Labs on November 14, 2022.

Ventus Therapeutics, Inc. announced that its Head of In Vitro and In Vivo Pharmacology, Anick Auger, presented an overview of the company’s novel NLRP3 inhibitor programs at the Fourth Inflammasome Therapeutics Summit, held from Nov. 29 to Dec. 1 in Boston.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Near-Term Launches + High-Value Pipeline Day on Monday, December 12, 2022 from 1:00 p.m. EST to 6:00 p.m. EST, with an approximately 30 minute break at the midpoint.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, announced another key addition to its executive leadership team with the appointment of Doug Cubbin as Chief Financial Officer.

The global Immune thrombocytopenia market is forecasted to grow at a rate of 6.7% from USD 2.18 billion in 2019 to USD 3.68 billion in 2030.